Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Febrile Neutropenia-Pipeline Review, H1 2015

Febrile Neutropenia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Febrile Neutropenia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Febrile Neutropenia-Pipeline Review, H1 2015', provides an overview of the Febrile Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Febrile Neutropenia Overview 7

Therapeutics Development 8

Pipeline Products for Febrile Neutropenia-Overview 8

Pipeline Products for Febrile Neutropenia-Comparative Analysis 9

Febrile Neutropenia-Therapeutics under Development by Companies 10

Febrile Neutropenia-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Febrile Neutropenia-Products under Development by Companies 14

Febrile Neutropenia-Companies Involved in Therapeutics Development 15

Apotex, Inc. 15

Biocon Limited 16

Coherus BioSciences, Inc. 17

Pfizer Inc. 18

Richter Gedeon Nyrt. 19

Sandoz International GmbH 20

Teva Pharmaceutical Industries Limited 21

Therapeutic Proteins International, LLC 22

Xenetic Biosciences plc 23

Febrile Neutropenia-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

(piperacillin sodium + tazobactam sodium)-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

filgrastim-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

filgrastim-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

filgrastim (recombinant)-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

lipegfilgrastim-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pegfilgrastim-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

pegfilgrastim-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

pegfilgrastim-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

pegfilgrastim-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

pegfilgrastim-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

pegfilgrastim-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Stimuxen-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Febrile Neutropenia-Recent Pipeline Updates 47

Febrile Neutropenia-Product Development Milestones 48

Featured News & Press Releases 48

Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 48

Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with -Lactamase Inhibitor 48

May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

Number of Products under Development for Febrile Neutropenia, H1 2015 8

Number of Products under Development for Febrile Neutropenia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Febrile Neutropenia-Pipeline by Apotex, Inc., H1 2015 15

Febrile Neutropenia-Pipeline by Biocon Limited, H1 2015 16

Febrile Neutropenia-Pipeline by Coherus BioSciences, Inc., H1 2015 17

Febrile Neutropenia-Pipeline by Pfizer Inc., H1 2015 18

Febrile Neutropenia-Pipeline by Richter Gedeon Nyrt., H1 2015 19

Febrile Neutropenia-Pipeline by Sandoz International GmbH, H1 2015 20

Febrile Neutropenia-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 21

Febrile Neutropenia-Pipeline by Therapeutic Proteins International, LLC, H1 2015 22

Febrile Neutropenia-Pipeline by Xenetic Biosciences plc, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Assessment by Combination Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 31

Number of Products by Stage and Molecule Type, H1 2015 33

Febrile Neutropenia Therapeutics-Recent Pipeline Updates, H1 2015 47

List of Figures

Number of Products under Development for Febrile Neutropenia, H1 2015 8

Number of Products under Development for Febrile Neutropenia-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31

Number of Products by Top 10 Molecule Types, H1 2015 32

Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Apotex, Inc.

Biocon Limited

Coherus BioSciences, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Sandoz International GmbH

Teva Pharmaceutical Industries Limited

Therapeutic Proteins International, LLC

Xenetic Biosciences plc

Febrile Neutropenia Therapeutic Products under Development, Key Players in Febrile Neutropenia Therapeutics, Febrile Neutropenia Pipeline Overview, Febrile Neutropenia Pipeline, Febrile Neutropenia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com